Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Safety and Efficacy of Eltrombopag in Japanese Subjects With Refractory, Moderate or More Severe Aplastic Anemia

Phase 2

Completed

Conditions: Cytopaenia

Interventions: Drug: Eltrombopag 12.5 mg
Drug: Eltrombopag 25 mg

First Posted Date: 2014-05-28

Last Posted Date: 2019-05-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT02148133

Locations: 🇯🇵
Novartis Investigative Site, Tokyo, Japan

Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma

Phase 1

Completed

Conditions: Relapsed and Refractory Multiple Myeloma

Interventions: Drug: LGH447
Drug: BYL719

First Posted Date: 2014-05-21

Last Posted Date: 2020-12-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 20

Registration Number: NCT02144038

Locations: 🇸🇬
Novartis Investigative Site, Singapore, Singapore
🇺🇸
University of Texas/MD Anderson Cancer Center Dept.ofMDAndersonCancerCtr(SC), Houston, Texas, United States
🇺🇸
Seattle Cancer Care Alliance Oncology Dept, Seattle, Washington, United States

and more 1 locations

Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients

Phase 1

Withdrawn

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Biological: LJM716
Biological: cetuximab

First Posted Date: 2014-05-21

Last Posted Date: 2016-04-21

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02143622

Study to Determine and Evaluate a Safe and Tolerated Dose of HDM201 in Patients With Selected Advanced Tumors That Are TP53wt

Phase 1

Completed

Conditions: Advanced Solid and Hematological TP53wt Tumors

Interventions: Drug: HDM201
Drug: ancillary treatment

First Posted Date: 2014-05-21

Last Posted Date: 2021-05-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 208

Registration Number: NCT02143635

Locations: 🇨🇳
Novartis Investigative Site, Taipei, Taiwan ROC, Taiwan
🇺🇸
Dana Farber Cancer Institute SC-6, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering Onc. Dep, New York, New York, United States

Efficacy and Safety of Lucentis® (Ranibizumab Intravitreal Injections) in Chilean Patients With Diabetic Macular Edema.

Phase 4

Completed

Conditions: Retinal Vein Occlusion
Age Related Macular Degeneration

Interventions: Drug: Ranibizumab Intravitreal injections

First Posted Date: 2014-05-16

Last Posted Date: 2019-02-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 21

Registration Number: NCT02140411

Locations: 🇨🇱
Novartis Investigative Site, Providencia, Santiago DE Chile, Chile

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VAY736 in Relapsed or Refractory CLL Patients

Phase 1

Terminated

Conditions: Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Interventions: Drug: VAY736

First Posted Date: 2014-05-14

Last Posted Date: 2018-02-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 3

Registration Number: NCT02137889

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer SC, Tampa, Florida, United States

Safety, Tolerability and Efficacy for CGF166 in Patients With Unilateral or Bilateral Severe-to-profound Hearing Loss

Phase 1

Completed

Conditions: Unilateral Severe to Profound Hearing Loss OR Bilateral Severe to Profound Hearing Loss

Interventions: Drug: CGF166

First Posted Date: 2014-05-07

Last Posted Date: 2021-10-08

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 22

Registration Number: NCT02132130

Locations: 🇺🇸
Novartis Investigative Site, Portland, Oregon, United States

A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients

Phase 4

Completed

Conditions: Age-Related Macular Degeneration

Interventions: Drug: Aflibercept 2.0 mg
Drug: Ranibizumab 0.5 mg

First Posted Date: 2014-05-02

Last Posted Date: 2019-06-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 281

Registration Number: NCT02130024

Locations: 🇦🇺
Novartis Investigative Site, Subiaco, Western Australia, Australia

Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma

Phase 3

Withdrawn

Conditions: Asthma

Interventions: Drug: NVA237
Drug: Placebo to NVA237
Drug: salbutamol/ albuterol

First Posted Date: 2014-05-01

Last Posted Date: 2015-04-13

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02127697

Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients

Phase 4

Completed

Conditions: Chronic Obstructive Pulmonary Disease
COPD

Interventions: Drug: QVA149
Drug: Tiotropium

First Posted Date: 2014-04-29

Last Posted Date: 2017-04-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 88

Registration Number: NCT02125734

Locations: 🇩🇪
Novartis Investigative Site, Warendorf, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy